FDA Approves Inluriyo for Advanced Breast Cancer
TUESDAY, Sept. 30, 2025 -- The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy (ET).
Inluriyo (200 mg tablets) is approved for once-daily, oral dosing. It binds, blocks, and facilitates the degradation of overactive estrogen receptors, helping to slow disease progression.
The approval is based on the phase 3 EMBER-3 trial, in which 256 patients with ESR1-mutated metastatic breast cancer received Inluriyo or ET as first-line treatment following recurrence. Results showed that Inluriyo reduced the risk for progression or death by 38 percent versus ET. Inluriyo also significantly improved progression-free survival versus fulvestrant or exemestane, with a median progression-free survival of 5.5 months versus 3.8 months (hazard ratio, 0.62).
"This represents an important advancement for patients with ESR1-mutated metastatic breast cancer, a mutation found in nearly half of patients who have taken hormone therapies, often contributing to treatment resistance," Komal Jhaveri, M.D., from the Memorial Sloan Kettering Cancer Center in New York City and a principal investigator of the EMBER-3 trial, said in a statement. "With its demonstrated efficacy, tolerability profile, and oral administration, this therapy provides a meaningful alternative treatment option for this patient population."
Approval of Inluriyo was granted to Eli Lilly.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Mammograms May Still Save Lives for Women in Their 80s, Study Finds
WEDNESDAY, Sept. 24, 2025 — Though most guidelines recommend mammograms up to age 74, new research suggests they can be valuable for women in their 80s, detecting breast...
Women With Dense Breasts Benefit From Advanced Cancer Screening Procedures
WEDNESDAY, Sept. 24, 2025 — Women with dense breasts could benefit from an advanced cancer screening procedure called molecular breast imaging (MBI), a new study says. The...
Can Mammograms Assess Women's Heart Health?
WEDNESDAY, Sept. 17, 2025 — Regular mammograms might offer a “two-for-one” opportunity to protect women’s health, a new study says. Mammograms can be used...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.